Brandon Dyson, PharmD, BCPS

The discussion explores how Medicare's Part D smoothing program in 2025 might impact chronic lymphocytic leukemia patients’ access to and adherence to Bruton tyrosine kinase inhibitor therapies and how pharmacists can help navigate this new program. The session concludes with closing remarks.

The discussion addresses the economic impact of appropriate dose modifications on chronic lymphocytic leukemia management.

The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.

The discussion explores the frequency and impact of dose modifications due to adverse events, strategies for maintaining outcomes, monitoring protocols, and how these modifications affect long-term CLL therapy effectiveness and treatment decisions.

The discussion addresses when dose modifications are typically required in chronic lymphocytic leukemia treatment and identifies the most common reasons for these modifications.

The discussion covers proactive strategies and interventions for managing adverse events before dose modification and explores supportive care measures for chronic lymphocytic leukemia treatments, including variations based on specific Bruton tyrosine kinase inhibitors.

The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.

With the odds of getting into a program just a little better than 1 in 2, how can students make sure that they are successful?

This one piece of unlikely job advice has helped me tremendously throughout my career

Here are 3 books that will help make you a better pharmacist.

Every single milestone that stands between you and becoming a pharmacist requires passing a multiple choice test.

These are the techniques that got me through pharmacy school, the NAPLEX, and the BCPS exam.

Depending on your practice environment, you may not regularly encounter hypercalcemia.

Changing your self-view from

To help prevent and treat neutropenia, we routinely use Granulocyte Colony Stimulating Factors (G-CSF) for patients undergoing myelosuppressive chemotherapy.